IRCT20191009045040N1CompletedPhase 3
Effects of Combined serum and fluticasone in chronic rhinosinusitis with polyposis in post op FESS patients
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 50 years (—)
- Sex
- All
Inclusion Criteria
- •Patients between the ages of 18 and 50, with chronic rhinosinusitis with polyposis
Exclusion Criteria
- •without mucociliary disease, heart disease, diabetes, and no history of malignancy
Investigators
Similar Trials
Completed
Not Applicable
The effect of combination therapy of fluticasone furoate nasal spray with levocetirizine hydrochloride in patients with Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).Japanese cedar pollinosisJPRN-UMIN000006502ippon Medical School42
Completed
Not Applicable
Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in JapaCOPDJPRN-UMIN000007544Kyusyu Asthma & COPD Forum1,008
Completed
Not Applicable
Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in JapaCOPDJPRN-UMIN000003403Kyusyu Asthma & COPD Forum1,008
Active, not recruiting
Phase 1
Efficacy of Fluticasone Propionate associated With Salmeterol underwent allogeneic hematopoietic stem cell transplantatioBronchiolitis Obliterative Syndrome after hematopoietic stem cell transplantation (HSCT)..EUCTR2020-003010-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)243
Active, not recruiting
Phase 1
Fludrocortisone in great premature babies.Great prematurityMedDRA version: 19.0Level: LLTClassification code 10053593Term: Premature baby 26 to 32 weeksSystem Organ Class: 100000004868EUCTR2016-000649-30-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)66